Abstract: Since our first report in 1987 to the XIth EULAR Congress of Rheumatology several reports had proved the efficacy of pulsed cyclophosphamide (PCP) in severe posterior uveitis (PU) and retinal vasculitis (RV) of Behcet's Disease (BD). The aim of this report is to show the outcome of 45 patients who have been followed for more than 2 years. PCP was administered as lg/m2/body surface, once per month, with 0.5 mg ...
Abstract: Posterior uveitis and retinal vasculitis are the most serious lesions of ocular Behcet. Pulse cyclophosphamide and cyclosporine A are the most efficient treatment. Oral cytotoxic drugs (cyclophosphamide, chlorambucil , and azathioprine) are less efficient. We present here our first impression on weekly pulsed methotrexate (MTX). MTX was administereted as 7.5 mg weekly in 3 divided doses, every 12 hours Prednisolone was given as 0.5 mg/kg/day. 23 patients with posterior uveitis (PU) ...
Abstract: PCP was administered as 1 g cyclophosphsmide/m2/body surface, once per month, with 0.5mg prednisolone/kg/day, to 71 patients with severe posterior uveitis (PU) and/or retinal vasculitis (RV) , A Disease Activity Index (DAI) was calculated for each section of each eye, before the first PCP and then after each one. When a remission was obtained the gap between, PCP was increased gradually and prednisolone was tapered. If the result remained ...
Abstract: Behcet's Disease (BD) is rather frequent in Iran. Near 200 new cases are seen every year, and this rate is going up every year. Ophthalmological manifestations are frequent (71%). Anterior uveitis (AU) is seen in 63% of patients. It is characterized by flare and cells in the anterior chamber. Hypopion, the classic lesion of the anterior chamber is transient and rarely seen in ophthalmologic examination. The AU progresses by successive ...
Abstract: PCP as lg/m2/body surface was given once per month, with 0.5 mg prednisolone/kg/day, to 155 patients with sever posterior uveitis (PU) and/ or retinal vasculitis (RV). A Disease Activity Index (DAI), based upon the inflammatory state of the eye, was calculated for each section of each eye before the first PCP and then after each PCP. When a remission was obtained the gap between PCP was increased gradually to 2, ...
Abstract: Systemic Lupus Erythematosus (SLE) is not a rare disease in Iran. In the past 13 years, we have seen 503 cases, with the following characteristics. Females 87%, males 13%, mean age 23 years (SD=11.25). Clinical manifestations were as follow: General manifestation in 57% (fever 52%, fatigue 39%, lack of appetite 18%, weight loss 36%). Mucocutaneous manifestations in 80% (malar rash 67%, discoid lesions 9%, photosensitivity 45%, alopecia 9%, Raynaud's phenomenon ...
Abstract: Ophthalmologic manifestations of BD, especially posterior uveitis and retinal vasculitis are resistant to most treatments, leading to sever loss of vision. Cytotoxic drugs, especially chlorambucil and cyclophosphamide (CP) are effective in some patients. In a preliminary report to the XI EULAR Congress of Rheumatology we demonstrated the efficacy of PTCP in these lesions. PTCP was performed by perfusion of 1 g. CP per square meter of body surface in 500 ...
Abstract: PT was performed by 2 methodes: 1- Needle prick. 2-- Intra dermal injection of normal salin. 83 % of BD patients presented a positive PT. Control subjects were composed of 101 healthy person, 46 Rheumatoid Arthritis, 5 Ankylosing Spondylitis, 18 Systemic Lupus Erythematosus (SLE). 3 Sclerodermia, and 1 permatomyositis. Among them 16% presented a positive PT. Only 3% had a positive PT with both needle prick and normal salin method. ...
Abstract: Patients with sever posterior uveitis and/or retinal vasculitis, and unresponsive to oral cytatoxic drugs and/or high doses steroids, were selected for this study. Pulse cyclophosphamide (PCP) was performed by perfusion of 1 g cyclophosphalnide per square meter of body surface in 500 ml of normal saline. PCP was repeated every month after a new evaluation of the patient. 30 mg of prednisolone/day was also given. Actually 102 patients are receiving ...
Abstract: In a separate report we demonstrated that B5 cluster antigens acts as a leading factor for ocular injuries. The question is why in some patients, these antigens does not produce the same lesions. This may be due to a genetic factor(s) which determine resistance to ocular lesions. Two HLA antigens attracted our attention as possible factors. One from the class I (CW4), and the other from the class II (DQW1). DQW1 ...